Moderna gets EMA review for Omicron BA.4/BA.5 targeting booster shot for aged 12, above
artJazz


The European Medicines Agency (EMA) accepted Moderna's (NASDAQ:MRNA) application for conditional marketing authorization of a 50 Âµg booster dose of the Omicron-containing bivalent COVID booster vaccine mRNA-1273.222 (Spikevax bivalent Original/Omicron BA.4-5) in adults 12 years and older.
Spikevax bivalent Original/Omicron BA.4-5 is a next-generation bivalent vaccine that contains 25 Âµg of mRNA-1273 (Spikevax) and 25 Âµg of a vaccine targeting the Omicron variant BA.4/BA.5, Moderna said in a Sept. 28 press release.

"Following the recent approval of our BA.1 targeting vaccine in Europe, our BA.4/BA5 Omicron targeting vaccine will now bring a second option to help protect people across Europe as we head into the winter months," said Moderna CEO StÃ©phane Bancel.
MRNA +0.14% to $122.40 premarket Sept. 28